|
1）Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365(9464): 1054-61
|
|
|
|
2）James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434(7037): 1144-8
|
|
|
|
|
|
3）Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myelo-proliferative disorders. N Engl J Med. 2005; 352(17): 1779-90
|
|
|
|
|
4）Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005; 7(4): 387-97
|
|
|
|
|
|
5）Levine RL, Pardanani A, Tefferi A, et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007; 7(9): 673-83
|
|
|
|
|
|
6）Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer. 2009; 115(17): 3842-7
|
|
|
|
|
|
7）Lacout C, Pisani DF, Tulliez M, et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 2006; 108(5): 1652-60
|
|
|
|
|
|
8）Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 2008; 22(7): 1299-307
|
|
|
|
|
|
9）De Stefano V, Rossi E, Za T, Ciminello A, et al. JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic or cerebral vein thrombosis. Am J Hematol. 2011; 86(6): 526-8
|
|
|
|
|
|
10）Patel RK, Lea NC, Heneghan MA, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology. 2006; 130(7): 2031-8
|
|
|
|
|
|
11）Colaizzo D, Amitrano L, Tiscia GL, et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost. 2007; 5(1): 55-61
|
|
|
|
|
|
12）Boissinot M, Lippert E, Girodon F, et al. Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous mega-karyocytic colonies in patients with splanchnic vein thrombosis. Blood. 2006; 108(9): 3223-4
|
|
|
|
|
|
13）Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011; 117(22): 5857-9
|
|
|
|
|
|
14）Jones AV, Chase A, Silver RT, et al. JAK2 haplo-type is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet. 2009; 41(4): 446-9
|
|
|
|
|
|
15）Kilpivaara O, Mukherjee S, Schram AM, et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2 (V617F)-positive myeloproliferative neoplasms. Nat Genet. 2009; 41(4): 455-9
|
|
|
|
|
|
16）Olcaydu D, Harutyunyan A, Jager R, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet. 2009; 41(4): 450-4
|
|
|
|
|
|
17）Smalberg JH, Koehler E, Darwish Murad S, et al. The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis. Blood. 2011; 117(15): 3968-73
|
|
|
|
|
|
18）Kouroupi E, Kiladjian JJ, Chomienne C, et al. The JAK2 46/1 haplotype in splanchnic vein thrombosis. Blood. 2011; 117(21): 5777-8
|
|
|
|
|
|
19）Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004; 350(2): 114-24
|
|
|
|
|
|
20）Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005; 366(9501): 1945-53
|
|
|
|
|
|
21）Panova-Noeva M, Marchetti M, Buoro S, et al. JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. Blood. 2011; 118(9): 2599-601
|
|
|
|
|
|
22）Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366(9): 787-98
|
|
|
|
|
|
23）Verstovsek S, Passamonti F, Rambaldi A, et al. Durable responses with the JAK1/JAK2 inhibitor, INB018424, in patients with polycythemia vera (PV) and essential thrombocythemia (ET) refractory or intolerant to hydroxyurea. 53rd ASH Annual Meeting and Exposition 2011
|
|
|
|
|